Loading
MN
Merus N.V. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Dec 2025.
Merus N.V.: what insiders have been doing
Merus N.V., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 4 insiders have disclosed 10 filings since 18 October 2025.
Every open-market trade in the period is a purchase: 4 purchases worth €29.0M, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Genmab A/S filed the largest purchase, €17.5M, on 22 December 2025.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 10 filings, this issuer sits below that mark. Since 2021, the database holds 8 purchases and 7 sales by insiders of the company.
The latest purchase dates back some time: it was published 292 days ago, on 30 December 2025. Typically, a trade is published a median of 4 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
45
Thresholds
n/a
Buy Volume
€30M
8 ops. · all time
Sell Volume
€32M
7 ops. · all time
Who traded when
BuySaleGenmab A/S4 buys
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$31.1M
Net income-US$185.4M-595.9% margin
Last declaration on 30 December 2025
Declarations45 total
2,978 shares@ US$97.000.8% of flowCommon Shares, nominal value EUR 0.09 per shareSEC:0001193125-25-337324:0
Canonical exit: 26 Mar 2026 (T+90)
15,710 shares@ US$97.004.5% of flowCommon Shares, nominal value EUR 0.09 per shareSEC:0001193125-25-335521:0
Canonical exit: 22 Mar 2026 (T+90)
212,177 shares@ US$97.0060.4% of flowCommon Shares, nominal value EUR 0.09 per shareSEC:0001193125-25-328955:0
Canonical exit: 18 Mar 2026 (T+90)
120,752 shares@ US$97.0034.3% of flowCommon Shares, nominal value EUR 0.09 per shareSEC:0001193125-25-325265:0
Canonical exit: 16 Mar 2026 (T+90)
30,297 shares@ US$97.0070.7% of flowCommon SharesSEC:0001193125-25-317947:0
11,002 shares@ US$97.0097.1% of flowCommon SharesSEC:0001193125-25-317941:0
73,576 shares@ US$97.0096.5% of flowCommon SharesSEC:0001193125-25-317936:0
800 shares@ US$18.611.4% of flowCommon SharesSEC:0001193125-25-314468:0
30,297 shares0Common SharesSEC:0001193125-25-302579:0
800 sharesCommon SharesSEC:0001193125-25-302551:0
25,000 shares@ US$24.4325.9% of flowCommon SharesSEC:0000950170-25-096919:0
6,695 shares@ US$18.615.2% of flowCommon SharesSEC:0000950170-25-095292:0
34,000 shares@ US$18.6127.0% of flowCommon SharesSEC:0000950170-25-089442:0
3,797 shares@ US$12.541.2% of flowCommon SharesSEC:0000950170-25-056278:0
5,000 shares0Common SharesSEC:0000950170-25-044359:0
2,000 sharesCommon SharesSEC:0000950170-25-044374:0
40,601 shares0Common SharesSEC:0000950170-25-024836:0
16,372 shares@ US$24.4310.9% of flowCommon SharesSEC:0000950170-25-022520:0
2,500 sharesCommon SharesSEC:0000950170-24-099825:0
2,547 shares@ US$17.942.1% of flowCommon SharesSEC:0000950170-24-079035:0
8,423 shares@ US$25.9010.0% of flowCommon SharesSEC:0000950170-24-075625:0
500 sharesCommon SharesSEC:0000950170-24-072536:0
1,000 sharesCommon SharesSEC:0000950170-24-069872:0
115 shares@ US$26.680.3% of flowCommon SharesSEC:0001209191-23-059328:0
21,100 sharesCommon SharesSEC:0001209191-23-058994:0
25 of 45 declarations
About Merus N.V.
Merus N.V. is a biotechnology company listed on the NASDAQ in the United States under the ticker MRUS, and it is best known for its focus on precision oncology. Although the company is incorporated in the Netherlands, it operates with a dual footprint: its principal executive presence is in Utrecht, the Netherlands, and it maintains a U.S. office in Cambridge, Massachusetts. That transatlantic structure is typical of many European biotech names that rely on U.S. capital markets and U.S.-centric clinical/regulatory execution. Merus is not yet a commercial-stage pharmaceutical company; it remains a clinical-stage oncology business, which means its valuation is primarily driven by clinical data, regulatory milestones, partnership potential, and financing capacity rather than product sales.
Founded in the 2000s, Merus built its scientific identity around proprietary multispecific antibody engineering. The company’s core platforms include Biclonics®, Triclonics®, and ADClonics®, reflecting its strategy to design full-length antibody therapeutics that can engage more than one biological target. In practical terms, the company is trying to address hard-to-treat cancers by improving potency, specificity, and resistance management relative to traditional single-target biologics. Merus’s lead asset is petosemtamab, a bispecific antibody that has become the centerpiece of the pipeline. In 2025, Merus reported interim clinical data for petosemtamab in head and neck squamous cell carcinoma and metastatic colorectal cancer, and the company has indicated that additional phase 3 readouts could arrive in 2026. The company also has other programs, including zenocutuzumab, which was highlighted in a New England Journal of Medicine publication in 2025.
Read moreShow less
From a competitive standpoint, Merus operates in a crowded oncology innovation landscape dominated by large pharma companies, well-capitalized biotech peers, and numerous antibody-platform developers. Its competitive edge lies in scientific differentiation rather than commercial scale. Investors typically assess Merus based on target biology, early-to-mid-stage efficacy signals, safety data, and the probability of advancing into pivotal development or securing strategic partnerships. Recent corporate highlights include the U.S. FDA’s Breakthrough Therapy Designation for petosemtamab in first-line PD-L1-positive head and neck squamous cell carcinoma, positive interim clinical updates in 2025, a public equity offering in June 2025, and a transaction agreement with Genmab announced in September 2025. For French-speaking investors in France, Belgium, and Switzerland, MRUS represents a high-risk, high-upside oncology biotech story tied to clinical execution and deal activity, with the market listing on NASDAQ in the United States adding liquidity and visibility but not reducing the inherent development risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
